Soligenix Current Ratio 2010-2022 | SNGX
Soligenix current ratio from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Soligenix Current Ratio Historical Data |
Date |
Current Assets |
Current Liabilities |
Current Ratio |
2022-09-30 |
$0.02B |
$0.01B |
1.81 |
2022-06-30 |
$0.02B |
$0.01B |
2.36 |
2022-03-31 |
$0.02B |
$0.01B |
3.25 |
2021-12-31 |
$0.03B |
$0.01B |
4.22 |
2021-09-30 |
$0.03B |
$0.01B |
6.14 |
2021-06-30 |
$0.03B |
$0.00B |
7.12 |
2021-03-31 |
$0.03B |
$0.00B |
7.27 |
2020-12-31 |
$0.02B |
$0.01B |
3.20 |
2020-09-30 |
$0.01B |
$0.01B |
2.30 |
2020-06-30 |
$0.01B |
$0.01B |
2.00 |
2020-03-31 |
$0.01B |
$0.01B |
1.51 |
2019-12-31 |
$0.01B |
$0.01B |
1.19 |
2019-09-30 |
$0.01B |
$0.01B |
1.42 |
2019-06-30 |
$0.01B |
$0.01B |
1.60 |
2019-03-31 |
$0.01B |
$0.00B |
2.20 |
2018-12-31 |
$0.01B |
$0.00B |
2.46 |
2018-09-30 |
$0.01B |
$0.00B |
3.27 |
2018-06-30 |
$0.01B |
$0.00B |
1.67 |
2018-03-31 |
$0.01B |
$0.00B |
2.16 |
2017-12-31 |
$0.01B |
$0.00B |
2.92 |
2017-09-30 |
$0.01B |
$0.00B |
2.13 |
2017-06-30 |
$0.01B |
$0.00B |
2.11 |
2017-03-31 |
$0.01B |
$0.00B |
3.19 |
2016-12-31 |
$0.01B |
$0.00B |
3.52 |
2016-09-30 |
$0.01B |
$0.01B |
1.36 |
2016-06-30 |
$0.01B |
$0.01B |
0.97 |
2016-03-31 |
$0.01B |
$0.01B |
0.81 |
2015-12-31 |
$0.01B |
$0.01B |
0.97 |
2015-09-30 |
$0.01B |
$0.01B |
0.89 |
2015-06-30 |
$0.01B |
$0.01B |
0.56 |
2015-03-31 |
$0.01B |
$0.01B |
0.71 |
2014-12-31 |
$0.01B |
$0.01B |
0.91 |
2014-09-30 |
$0.01B |
$0.01B |
0.55 |
2014-06-30 |
$0.01B |
$0.01B |
0.52 |
2014-03-31 |
$0.01B |
$0.01B |
0.58 |
2013-12-31 |
$0.01B |
$0.01B |
0.76 |
2013-09-30 |
$0.01B |
$0.01B |
0.62 |
2013-06-30 |
$0.01B |
$0.01B |
1.25 |
2013-03-31 |
$0.00B |
$0.00B |
2.05 |
2012-12-31 |
$0.00B |
$0.00B |
3.32 |
2012-09-30 |
$0.00B |
$0.00B |
3.94 |
2012-06-30 |
$0.01B |
$0.00B |
3.81 |
2012-03-31 |
$0.01B |
$0.00B |
4.30 |
2011-12-31 |
$0.01B |
$0.00B |
4.98 |
2011-09-30 |
$0.01B |
$0.00B |
5.43 |
2011-06-30 |
$0.01B |
$0.00B |
3.22 |
2011-03-31 |
$0.01B |
$0.00B |
4.28 |
2010-12-31 |
$0.01B |
$0.00B |
4.19 |
2010-09-30 |
$0.01B |
$0.00B |
6.19 |
2010-06-30 |
$0.01B |
$0.00B |
6.13 |
2010-03-31 |
$0.01B |
$0.00B |
6.22 |
2009-12-31 |
$0.01B |
$0.00B |
6.53 |
2009-09-30 |
$0.01B |
$0.00B |
4.97 |
2009-06-30 |
$0.01B |
$0.00B |
4.02 |
2009-03-31 |
$0.01B |
$0.00B |
5.66 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$0.020B |
$0.001B |
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec ? (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM TM Leuprolide. The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury programs from early stage development to advanced development and manufacturing. Soligenix, Inc, formerly known as DOR BioPharma, Inc, is headquartered in Princeton, New Jersey.
|